Literature DB >> 1080641

Penetration of amikacin into the aphakic eye.

R T Kasbeer, G A Peyman, D R May, P I Homer.   

Abstract

An experiment was designed to see if an aminoglycoside antibiotic, amikacin, would penetrate the vitreous of rabbits in greater concentrations in the postoperative aphakic eye than in the normal eye. Phakic and aphakic eyes were treated with amikacin by topical, subconjunctival, and intramuscular methods separately and combined. Bioassays of aqueous, anterior vitreous, and posterior vitreous revealed that concentrations of amikacin in ocular fluids after intramuscular administration were greater in the aphakic eye as compared to the normal eye; however, concentrations in the vitreous did not reach reliably bactericidal concentrations even when all three methods of administration were combined.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1080641     DOI: 10.1007/bf00410030

Source DB:  PubMed          Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol        ISSN: 0065-6100


  24 in total

1.  The penetration of several new penicillins into the tissues of the eye.

Authors:  H A DEUR; E R MAAS
Journal:  Ophthalmologica       Date:  1962       Impact factor: 3.250

2.  Eye infections following cataract extraction, with special reference to the role of Staphylococcus aureus.

Authors:  D LOCATCHER-KHORAZO; E GUTIERREZ
Journal:  Am J Ophthalmol       Date:  1956-06       Impact factor: 5.258

3.  Intraocular penetration of streptomycin following systemic and local administration.

Authors:  I H LEOPOLD; A NICHOLS
Journal:  Arch Ophthal       Date:  1946-01

4.  In vitro studies of BB-K8, a new aminoglycoside antibiotic.

Authors:  G P Bodey; D Stewart
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

5.  BB-K8: A new aminoglycoside for intravitreal injection in bacterial endophthalmitis.

Authors:  P Nelsen; G A Peyman; T O Bennett
Journal:  Am J Ophthalmol       Date:  1974-07       Impact factor: 5.258

6.  Ocular penetration and tolerance of gentamicin.

Authors:  F P Furgiuele
Journal:  Am J Ophthalmol       Date:  1967-09       Impact factor: 5.258

7.  Amikacin (BB-K8) treatment of multiple-drug resistant Proteus infections.

Authors:  P M Sharp; C A Saenz; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

8.  Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics.

Authors:  K E Price; T A Pursiano; M D DeFuria
Journal:  Antimicrob Agents Chemother       Date:  1974-02       Impact factor: 5.191

9.  Comparative in vitro activity of three aminoglycosidic antibiotics: BB-K8, kanamycin, and gentamicin.

Authors:  P K Yu; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

10.  In vitro evaluation of a new aminoglycoside derivative of kanamycin, a comparison with tobramycin and gentamycin.

Authors:  K Ries; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

View more
  5 in total

1.  Management of endophthalmitis with pars plana vitrectomy.

Authors:  G A Peyman; M Raichand; T O Bennett
Journal:  Br J Ophthalmol       Date:  1980-07       Impact factor: 4.638

Review 2.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

Review 3.  Antimicrobial guide to posterior segment infections.

Authors:  Tapan P Patel; David N Zacks; Vaidehi S Dedania
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-06       Impact factor: 3.117

4.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993

5.  Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis.

Authors:  Michael Engelbert; Herminia Miño de Kaspar; Martin Thiel; Thomas Grasbon; Christopher N Ta; Markus Schulze-Schwering; Volker Klauss; Anselm Kampik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-02-24       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.